HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.
Also called NCT05623189
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 218 participants
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
- Registry
-
NCT05623189
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Hong Kong SAR China, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT05623189. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-27 (actual); primary completion 2025-03-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
- Acronym
- CENTRICITY
- Condition
- Nonalcoholic Steatohepatitis (NASH)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HTD1801
- Intervention (Drug)
- Placebo
- Lead sponsor
- HighTide Therapeutics (Hong Kong) Limited
Record details
- Record id
cardio:ct-nct05623189- Content hash
6873f3d72c5936e256b25646be12c04eede155a5f55dd8e391c760c57de752af